Seres Completes Enrollment for SER-287 Phase 1b Clinical Trial in Patients with UC
News
All patients with mild-to-moderate ulcerative colitis (UC) have been enrolled in Seres Therapeutics‘ ongoing Phase 1b clinical study evaluating the company’s drug therapy candidate, SER-287. The ongoing randomized, placebo-controlled, multiple-dose, ... Read more